Dr. Alo argues Ozempic is more than a weight loss drug, crediting the SELECT trial with a 20% drop in heart attacks, strokes and cardiovascular deaths.
Recap by typeshit. Post by @dr.alo on Instagram.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
TheStreet looks at what that means for patients paying up to $1,500 a month for peptide therapy and how the ruling could affect what they pay.
The ingredient maker says it surveyed people on GLP-1 drugs about their beauty needs. It's a company marketing post with few findings shared.
Loading…